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Introduction
Interleukin (IL)-12p70 is a heterodimer consisting of cova-
lently linked p35 and p40 subunits encoded by two distinct
genes [1]. This heterodimer, which is produced at high
levels by dendritic cells (DCs), drives naive T cells to differ-
entiate into IFN-γ producing T helper (Th) 1 cells [1]. The
p40 subunit of IL-12 is produced in excess in relation to
the heterodimer and also forms a homodimer that seems to
antagonize the function of IL-12p70 [1,2]. Upregulation of
both p35 and p40 mRNA expression is needed for the
secretion of IL-12p70, and there is increasing evidence
that the expression of these subunits is independently reg-
ulated. The levels of mRNA for these subunits do not corre-
spond to the levels of secreted IL-12p70, because the
formation of the heterodimer is regulated also at transla-
tional or post-translational levels [3].
DCs, monocytes, and macrophages are the main produc-
ers of IL-12p70 [1]. Various microbial stimuli induce the
production of IL-12 by DCs in the early phase of the
immune response. CD40 ligation by CD154 expressed on
activated CD4+ T cells seems to be the major inducer of
IL-12p70 production [4,5]. DCs produce IL-12p70 only
for a short time in the early phase of their maturation and
then become exhausted for IL-12 production [1]. Macro-
phages, by contrast, generally need additional priming
with IFN-γ or IL-4 in order to secrete IL-12p70 [1,6]. IFN-γ
and IL-4 also enhance the production of IL-12p70 by DCs
[6,7]. IL-12 synthesis is limited by several mechanisms,
including anti-inflammatory cytokines such as IL-10 and
tranforming growth factor beta [1]. IL-12 production has
also been shown to be downregulated by IFN-α and -β,
ligation of Fcγ receptors, complement receptors or
BSA = bovine serum albumin; DC = dendritic cell; ELISA = enzyme-linked immunosorbent assay; GM-CSF = granulocyte/macrophage-colony-stim-
ulating factor; IFN = interferon; IL = interleukin; LPS = lipopolysaccharide; mAb = monoclonal antibody; MACS = magnetic cell sorting; PB =
peripheral blood; PBMC = peripheral blood mononuclear cell; RA = rheumatoid arthritis; RF = rheumatoid factor; RT-PCR = reverse transcriptase
polymerase chain reaction; SF = synovial fluid; SFMC = synovial fluid mononuclear cell; Th = T helper; TNF = tumor necrosis factor.
Available online http://arthritis-research.com/4/5/R9
Research article
Regulation of CD154-induced interleukin-12 production in
synovial fluid macrophages
Milja Möttönen1,2, Pia Isomäki2, Reijo Luukkainen3 and Olli Lassila1,2
1Turku Graduate School of Biomedical Sciences, Turku University, Turku, Finland
2Department of Medical Microbiology, Turku University, Turku, Finland
3Satalinna Hospital, Harjavalta, Finland
Corresponding author: Milja Möttönen (e-mail: milja.mottonen@utu.fi)
Received: 12 March 2002    Revisions received: 20 June 2002    Accepted: 1 July 2002    Published: 26 July 2002
Arthritis Res 2002, 4:R9
© 2002 Möttönen et al., licensee BioMed Central Ltd (Print ISSN 1465-9905; Online ISSN 1465-9913)
Abstract
Interleukin (IL)-12, being a major cytokine that induces T helper
(Th) 1 differentiation and inflammatory response, has been
postulated to be an important mediator of synovial inflammation
in rheumatoid arthritis (RA). However, the regulation of IL-12
production in RA has not been elucidated. Our knowledge is
mainly based on studies of the production of IL-12p40 and not
the functional IL-12p70 heterodimer. We have studied the
CD154-induced IL-12p40 and IL-12p70 production by
synovial fluid (SF) macrophages from patients with RA. CD40
ligation induced the secretion of IL-12p40 but not IL-12p70.
The observed increase in IL-10 and tumor necrosis factor
(TNF)-α production indicated that SF macrophages responded
to CD40 ligation. The expression of p40 mRNA was increased
significantly and remained upregulated after CD40 ligation,
whereas the increase of p35 transcript expression was
observed only transiently and at a lower level. We further
observed that dendritic cells (DCs) derived in vitro from SF
macrophages produced IL-12p70. Most importantly, IL-4 and
IL-13 primed SF macrophages to produce IL-12p70, whereas
IFN-γ was not observed to activate IL-12p70 production in
these cells, in contrast with normal peripheral blood
monocytes. These results provide novel information about the
regulation of IL-12p70 production and the function of the
cytokine network in RA.
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scavenger receptors on macrophages, prostaglandin E2,
and corticosteroids [8–11]. Further, proinflammatory
cytokines, such as tumor necrosis factor (TNF)-α and
chemoattractants (macrophage chemoattractant proteins
1 to 4 and C5a) inhibit IL-12 production in macrophages
[12–14].
IL-12 has been suggested to be the predominant cytokine
inducing Th1-like phenotype of CD4+ T cells in rheuma-
toid arthritis (RA) [15–17], although the evidence is rather
indirect. Although synovial T cells are of ‘memory’ pheno-
type [16], IL-12 can significantly enhance their IFN-γ pro-
duction in synergy with IL-15 and IL-18 [17–19]. Studies
in murine collagen-induced arthritis, an animal model of
RA, suggest that IL-12 can promote arthritis in vivo.
Exogenous IL-12 or transient systemic overexpression of
heterodimeric IL-12 exacerbates collagen-induced arthritis
[20,21]. In contrast, neutralization of IL-12 attenuates the
severity of collagen-induced arthritis, and both the inci-
dence and the severity of the disease are reduced in
IL-12-deficient mice [22,23]. However, the role of IL-12
seems to be biphasic, as a low dose or early administra-
tion promotes the disease, whereas a high dose or admin-
istration during the chronic phase can suppress
established disease [20,24,25]. In RA, increased levels of
IL-12p70 and p40 proteins have been detected in synovial
tissue homogenates in comparison with those from
patients with osteoarthritis or ankylosing spondylitis [26],
and RA synovial cells have been shown to spontaneously
produce low levels of p40 and p70 proteins [18,26].
Immunohistochemical and flow cytometric analyses have
suggested that CD68+ macrophages are the main source
of synovial IL-12 [18,26,27].
Previous studies suggest that IL-12 plays an important
role in synovial inflammation in RA. However, the regula-
tion of synovial IL-12p70 production has not been ade-
quately studied. Mainly IL-12p40 production has been
addressed [26], and therefore the regulation of IL-12p70
production has not been elucidated. Since triggering of
CD40 is the main physiological inducer of IL-12 produc-
tion, and we have earlier shown that synovial fluid (SF)
macrophages express increased levels of CD40 [28], we
studied the CD154-induced production of IL-12p40 and
p70 by SF macrophages. We show that SF
macrophages produce IL-12p40 but not p70 after CD40
ligation. The expression of p40 mRNA is increased signifi-
cantly and remains upregulated after CD40 ligation,
whereas p35 transcript expression increases only tran-
siently and at a lower level. Furthermore, we show that SF
macrophages differentiate in vitro into DCs producing IL-
12p70. Unlike priming with IL-4 or IL-13, which was
observed to activate IL-12p70 production in SF
macrophages, priming with IFN-γ did not activate IL-
12p70 production, in contrast to what was observed in
normal peripheral blood (PB) monocytes.
Materials and methods
Patients
A total of 50 patients with RA (37 women and 13 men)
were enrolled in this study. SF samples from the inflamed
knee joints were collected by needle aspiration into
heparinized tubes. RA was determined by the criteria of
the American College of Rheumatology (formerly the
American Rheumatism Association) [29]. The median age
of the patients was 61 years (range 29–86) and the
median duration of the disease was 14 years (range
0.25–42). Seven patients had seronegative RA. Forty-five
of the patients were treated with disease-modifying
antirheumatic drugs, 36 with corticosteroids, and 41 with
nonsteroidal anti-inflammatory drugs. Buffy coats from
healthy blood donors were received from the Finnish Red
Cross. This study was approved by the ethical committee
of Turku University Central Hospital.
Reagents
All cytokines used were purified recombinant human pro-
teins. IFN-γ was obtained from Schering-Plough Research
Institute (Kenilworth, NJ, USA). Granulocyte/macrophage-
colony-stimulating factor (GM-CSF) (Leucomax) was pur-
chased from Schering Plough/Sandoz (Innishannon,
Ireland) and IL-4 was purchased from R&D Systems
(Abingdon, UK). IL-13, neutralizing mouse antihuman IL-10
monoclonal antibody (mAb) (9D7), and nonspecific mouse
IgG1 were from DNAX Research Institute (Palo Alto, CA,
USA). Neutralizing antihuman TNF-α mAb was purchased
from Genzyme (Cambridge, MA, USA) and lipopolysac-
charide (LPS) (Escherichia coli serotype 0127:B8) from
Sigma (St Louis, MO, USA). CD154-transfected J558L
cells (J558L-CD154) and control J558L cells were kindly
provided by Dr P Lane (Birmingham, UK) and have been
previously described [30]. Antihuman CD3 and CD19
microbeads for magnetic cell sorting (MACS) were
obtained from Miltenyi Biotec (Auburn, CA, USA). Fluores-
cein-isothiocyanate-conjugated antihuman CD14 and non-
specific mouse IgG, and phycoerythrin-conjugated
antihuman CD14, CD80, HLA-DR, and nonspecific mouse
IgG, were purchased from Becton Dickinson (San Jose,
CA, USA). Fluorescein-isothiocyanate-conjugated antihu-
man CD40, phycoerythrin-conjugated antihuman CD86,
and unconjugated antihuman CD1a were obtained from
PharMingen (San Diego, CA, USA). Nonconjugated antihu-
man CD83 was a gift from Dr TF Tedder (Duke University
Medical Center, Durham, NC, USA). Phycoerythrin-
conjugated goat antimouse IgG1 and IgG2b were pur-
chased from Southern Biotechnology Associated, Inc
(Birmingham, AL, USA). mAbs 2-6 (IgG1, antichicken
CD4) and mAbs 9-8 (IgG2b, antichicken CD8α) were
used as negative controls.
Cell preparations
SF samples were treated with bovine testicular
hyaluronidase (10 µg/ml; Type IV-S, Sigma, Steinheim,
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Germany) for 15 minutes at 37°C. Synovial fluid mononu-
clear cells (SFMCs) from patients and peripheral blood
mononuclear cells (PBMCs) from healthy controls were
isolated by Ficoll-Paque (Pharmacia, Uppsala, Sweden)
density gradient centrifugation and washed twice with
Hank’s buffered saline solution. Plastic-adherent SFMCs
and PBMCs were isolated by incubating the cells on
tissue-culture dishes (Falcon 1001, Becton Dickinson
Labware, Lincoln Park, NJ, USA) in RPMI 1640 (Gibco
BRL, Life Technologies, Paisley, Scotland) supplemented
with 5% AB-serum (Finnish Red Cross, Helsinki, Finland),
0.3 mg/ml L-glutamine (Gibco BRL), 25 mM HEPES
(Gibco BRL), 0.85 mg/ml NaHCO3 (Gibco BRL) and
100 µg/ml gentamicin (Biological Industries, Kibbutz Beit
Haemek, Israel) for 1 hour at 37°C. Adherent SFMCs and
PBMCs were suspended in Iscove’s modified Dulbecco’s
medium (Gibco BRL) supplemented with 10% heat-inacti-
vated fetal calf serum (HyClone Laboratories, Logan, UT,
USA), 0.1 mM 2-mercaptoethanol (Sigma, St Louis, MO,
USA), 10 mM HEPES, and 100 µg/ml of gentamicin. As
evaluated in seven samples using flow cytometry, adher-
ent SFMCs were 78 ± 11% CD14+ (mean ± SD).
However, 90 ± 6% of these cells had the light-scatter
characteristics of ‘monocytes/macrophages’, and are
hereafter called SF macrophages. As evaluated in three
samples, adherent PBMCs were 70 ± 9% CD14+. Of
these cells, 76 ± 2% had the light-scatter characteristics
of macrophages. To further purify the adherent PBMCs in
some experiments, CD3+ and CD19+ cells were removed
using MACS. In three of these samples, there were
78 ± 10% CD14+ cells and 91 ± 6% of the cells had the
light-scatter characteristics of macrophages. The results
obtained did not differ between adherent PBMCs and
adherent PBMCs depleted of CD3+ and CD19+ cells by
MACS, and these cells are hereafter called PB monocytes.
Cell cultures
J558L-CD154 transfectants and control J558L cells were
irradiated (30 Gy) before use as stimulators. SF macro-
phages or normal PB monocytes (0.5–1 × 106 cells/ml)
were cultured in Iscove’s modified Dulbecco’s medium +
10% fetal calf serum in a total volume of 1 ml with CD154
transfectants, control J558L cells, LPS (1 µg/ml; Sigma)
or in medium only, in 24-well plates (Costar, Cambridge,
MA, USA) for 24 or 72 hours. CD154 transfectants and
control J558L cells were used at a ratio of 1: 5 transfec-
tants:macrophages. To study the effect of IFN-γ on IL-12
production, SF macrophages and PB monocytes were
precultured with 10 or 100 ng/ml IFN-γ for 16 hours
before addition of the transfectants or LPS for a further
24 hours. To study the effects of endogenous TNF-α and
IL-10 on the production of IL-12, neutralizing antihuman
TNF-α mAbs, neutralizing anti-IL-10 mAbs, or nonspecific
mouse IgG1 (all 5 µg/ml) were added simultaneously with
or 24 hours before the transfectants or the control cells.
Alternatively, SF macrophages were first cultured with
neutralizing antibodies for 24 hours, followed by addition
of IFN-γ for 16 hours and then addition of the transfectants
for the last 24 hours of culture. To study the effects of IL-4
and IL-13 on IL-12 production, we cultured SF
macrophages in the presence of IL-4 or IL-13 (100 U/ml)
for 72 hours before stimulation with the transfectants or
the control cells for a further 24 hours. After the stimula-
tions, the culture supernatants were collected, cen-
trifuged, and separated from the pellet and frozen at
–70°C until used for enzyme-linked immunosorbent assay
(ELISA) determinations.
Generation of dendritic cells
0.5 × 106 SF macrophages from patients or PB mono-
cytes from healthy controls were cultured with IL-4
(500 U/ml) and GM-CSF (50 ng/ml) for 7 days in a total
volume of 1 ml on 24-well plates (Costar). The same con-
centrations of the cytokines were added every third day by
replacing 100 µl of the culture medium. On day 7, the
cells from both SF and PB had the typical phenotype of
monocyte-derived DCs [4,31]. On day 7, CD154 transfec-
tants (at a ratio of 1: 5 transfectants:DCs), control cells
(1: 5), or medium only was added to the cultures by
replacing 100 µl of the culture medium. After 24 hours,
the supernatants were collected, centrifuged, and sepa-
rated from the pellet and frozen at –70°C until they were
used for ELISA determinations. Cells were harvested and
the expression of cell-surface markers related to myeloid
DCs was analyzed using flow cytometry.
Measurement of cytokine levels
Cytokine levels in culture supernatants and SF were mea-
sured by cytokine-specific ELISAs. IL-12p40 and IL-
12p70 were measured using matched capture and
detection antibody pairs and standards purchased from
R&D Systems. Plates (Immulon, Dynatech Laboratories,
Chantilly, VA, USA) were prepared by coating with mono-
clonal capture antibodies (3 µg/ml antihuman IL-12p70
mAb or antihuman IL-12p40 mAb) overnight at room tem-
perature followed by three washes with washing buffer
(0.05% Tween 20 in phosphate-buffered saline solution)
and then blocking with phosphate-buffered saline solution
containing 1% BSA, 5% sucrose, and 0.05% NaN3 for
1 hour. After three washes, the samples and standards (IL-
12p70 or IL-12p40), resuspended in 0.1% BSA, 0.05%
Tween 20 in Tris-buffered saline solution, pH 7.3, were
added and incubated for 2 hours at room temperature.
After the washing procedure, the biotinylated detection
antibodies (350 ng/ml antihuman IL-12) were added for
2 hours. The plates were again washed three times and
horseradish peroxidase:streptavidin (1:20000, 100 µl/well;
43-4323, Zymed Laboratories, San Francisco, CA, USA)
was added for 20 minutes. The plates were washed and
substrate solution (100 µg/ml 3,3′,5,5′-tetramethylbenzi-
dine (Sigma), 0.003% H2O2 in 0.11 M acetate buffer,
pH 5.5) was added. After sufficient incubation time
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(usually 30 minutes) in the dark at room temperature,
1.8 M H2SO4 was added to stop the reaction. The plates
were immediately analyzed using a microtiter plate reader
(Labsystems Multiskan® PLUS, Labsystems, Helsinki,
Finland) set to 450 nm. The typical sensitivity of the assay
was 8 pg/ml for IL-12p70 and 31 pg/ml for IL-12p40. IL-
10 and TNF-α levels were measured using ELISA kits
obtained from CLB (Amsterdam, Netherlands), and the
sensitivity of the assays was 1 pg/ml. All ELISA determina-
tions were performed in duplicate. IgM rheumatoid factor
(RF) was detected in SF and serum samples using an in-
house enzyme immunoassay. To eliminate the possible
influence of RF in the IL-12 ELISAs, five pairs of SF and
serum samples from patients positive for RF were treated
for 1 hour at 4°C with fixed protein-A+ Staphylococcus
aureus cells (Zyzorbin, Zymed Laboratories). Samples
were then centrifuged at 10,000 rpm (10,280 g) for
5 minutes and supernatants were collected. This treat-
ment was performed three times and removed > 50% of
the IgM RF in the samples.
Isolation and analysis of mRNA by reverse transcriptase
polymerase chain reaction
Total RNA was extracted from 1.0 × 106 freshly isolated
SF macrophages or 1.0 × 106 SF macrophages cultured
with CD154 transfectants or control J558L cells for 6 or
24 hours using the Ultraspec-II RNA isolation system
(Biotecx Laboratories, Inc, Houston, Texas, USA). For con-
trols, total RNA was also isolated from 0.5 × 106 DCs
derived from SF macrophages and stimulated with
CD154 transfectants or control J558L cells for 24 hours,
and from 1.0 × 106 CD154 transfectants or control J558L
cells themselves. Total RNA was reverse transcribed
using avian myeloblastosis virus (1st Strand cDNA Synthe-
sis Kit for reverse transcriptase polymerase chain reaction
(RT-PCR) (Roche Diagnostics, Mannheim, Germany) in a
reaction volume of 20 µl in accordance with the manufac-
turer’s instructions. Two microliters of cDNA was then
used for PCR amplification in a 50-µl reaction mixture con-
taining 1 U of DynaZyme II DNA polymerase (Finnzymes
OY, Espoo, Finland), 5 µl of 10 × PCR Buffer (Finnzymes
OY), 0.2 mM of each dNTP, and 15 pmol/µl of each primer.
Housekeeping β-actin was amplified from the same pool of
cDNA. Avian myeloblastosis virus reverse transcriptase
was omitted from the control RT reactions. The following
primers were used: IL-12p35 sense 5′-TCAGCAACA-
TGCTCCAGAAGGC-3′; IL-12p35 antisense 5′-TGCATT-
CATGGTCTTGAACTCCACC-3′; IL-12p40 sense 5′-
AAGCAGCAGAGGCTCTTCTGA-3′; IL-12p40 antisense
5′-ACCTGAACGCAGAATGTCAGG-3′; β-actin sense 5′-
GGGTCAGAAGGATTCCTATG-3′; and β-actin antisense
5′-CCTTAATGTCACGCACGATTT-3′. Reactions were
incubated in The DNA Engine™ Peltier Thermal Cycler
(PTC-200) (MJ Research, Watertown, MA, USA) for 30
cycles (denaturation for 30 seconds at 95°C, annealing
for 30 seconds at 62°C [p35], 60°C [p40], or 57°C [β-
actin], and extension for 30 seconds at 72°C). PCR prod-
ucts were electrophoresed through a Seakem 1.5% agarose
gel (FMC Bioproducts, Rockland, ME, USA), and visualized
using ultraviolet light. Gels were denaturated in 0.4 M NaOH
and transferred to a Hybond-N+ membrane (Amersham, UK)
for southern hybridization in accordance with the manufac-
turer’s instructions. Oligonucleotide probes, specific for a
sequence internal to the primers used in the amplification,
were labeled with γ-(32P)ATP (PerkinElmer Life Sciences,
Boston, MA, USA) using T4 Polynucleotide Kinase
(Promega, Madison, WI, USA) for 5′ end labeling. The
oligonucleotide probes were: IL-12p35: 5′-TGCACTTCT-
GAAGAGATTGATCATGAAGAT-3′ and IL-12p40: 5′-
TGCTACACTCTCTGCAGACAGAGTCAGAG-3′.
Statistical analysis
In the analysis of the ELISA results, limit values of the
assays were used for values below the detection limit. The
Wilcoxon signed-rank test was used for paired samples
and the Mann–Whitney U test for unpaired data to evalu-
ate the significance of differences. Correlations were cal-
culated using Spearman’s rank correlation analysis.
Results
IL-12 levels are lower in synovial fluid than in sera from
patients with RA
We first studied the levels of IL-12p40 and IL-12p70 in
paired SF and serum samples from 35 patients with RA. IL-
12p40 was found (>31 pg/ml) in 18 of 35 (51%) SF
samples and in 21 of 35 (60%) serum samples studied,
while IL-12p70 was detected (>8 pg/ml) in 16 of 35 (46%)
SF samples and in 20 of 35 (57%) serum samples
(Table 1). The levels of both IL-12p40 and p70 were signifi-
cantly higher in serum than in SF (P < 0.05). A positive cor-
relation between the SF and serum levels of IL-12p40
(r = 0.612, P < 0.0005) and p70 (r = 0.672, P < 0.0001)
was found. In addition, positive correlations were found
between the levels of IL-12p40 and p70 in SF (r = 0.963,
P < 0.0001) and in serum (r = 0.959, P < 0.0001). To rule
out the possible effect of RF in the measurements of IL-
12p40 and p70, we determined the levels of RF in the same
SF and sera. RF was positive (>18 U/ml) in 25 of 35 (71%)
SF samples and in 28 of 35 (80%) serum samples (data not
shown). However, no correlations between the levels of RF
and IL-12p40 or p70 were found, either in SF or sera. Fur-
thermore, no significant differences in the levels of IL-12p40
before and after removal of RF were observed in five pairs of
serum and SF samples from patients positive for RF (SF:
mean ± SEM 485 ± 140 pg/ml and 359 ± 152 pg/ml,
respectively, and serum: 10,728 ± 6,272 pg/ml and
9,978 ± 5,874 pg/ml, respectively).
Synovial fluid macrophages produce IL-12p40 but not
IL-12p70 after CD40 ligation
We next analyzed the production of IL-12p40 and p70 by
SF macrophages in response to CD40 ligation. No pro-
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duction of IL-12p70 was observed spontaneously or in
response to CD40 ligation by SF macrophages or normal
PB monocytes when the cells were cultured for 72 hours
(Fig. 1a,c). The results were similar after 24 hours of
culture (data not shown). However, both SF macrophages
and PB monocytes produced substantial levels of
IL-12p40 after CD40 ligation when cultured for 72 hours
(see Fig. 1b,d). Significantly lower levels of p40, or none,
were detected after 24 hours of culture (data not shown).
After LPS stimulation, used as a control, neither type of
cells produced either IL-12p40 or IL-12p70 (see Fig. 1).
To determine whether SF macrophages were generally
unresponsive to CD40 ligation, we measured the levels of
IL-10 and TNF-α from the same culture supernatants.
Both CD40 ligation and LPS increased the production of
these cytokines (Table 2). CD40 ligation significantly
increased the production of TNF-α by SF macrophages
but not by PB monocytes.
Dendritic cells derived from synovial fluid macrophages
produce IL-12p70 in response to CD40 ligation
To investigate whether SF macrophages have the capacity
to differentiate into DCs capable of producing IL-12p70
after CD40 ligation, SF macrophages and PB monocytes
were cultured in the presence of IL-4 and GM-CSF for
7 days to induce their differentiation into immature DCs
[4,28,31]. These cells were then further stimulated with
CD154 transfectants for 24 hours. On day 8, cells cul-
tured in the presence of IL-4 and GM-CSF had a typical
phenotype of immature DCs, expressing CD1a, CD40,
CD80, CD86 and HLA-DR but not CD14. Cells stimu-
lated with CD154 transfectants upregulated the expres-
sion of CD83, a phenotypic marker for mature DCs (data
not shown). CD40 ligation induced the production of high
levels of IL-12p40 and p70 (Table 3).
Expression of p40 mRNA in synovial fluid macrophages
is increased more than p35 mRNA expression after
CD40 ligation
Because it is known that expression of p35 and p40
mRNA does not necessarily correlate with p70 produc-
tion, we analyzed the effects of CD40 ligation on the
expression of p35 and p40 transcripts in SF macrophages
by RT-PCR. Both transcripts were detectable in freshly
isolated SF macrophages (Fig. 2). SF macrophages stimu-
lated with CD154 transfectants for 6 or 24 hours
expressed higher levels of p40 than those cultured with
control J558L cells, demonstrating that CD40 ligation
increased the expression of p40. The expression of p35
mRNA was upregulated only slightly — less and more tran-
siently than that of p40. As a positive control, we studied
p35 and p40 transcript expression in SF macrophage-
derived DCs, which expressed high levels of both tran-
scripts after stimulation with CD154 transfectants. The
results from these RT-PCR analyses support those
obtained studying IL-12p70 and p40 production by
ELISA, showing that that low expression of p35 mRNA
may explain the lack of p70 protein production in SF
macrophages.
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Table 1
Levels of IL-12p40 and IL-12p70 in synovial fluid (SF) and sera
from patients with rheumatoid arthritis
Cytokine concentration (pg/ml)a
IL-12p70 IL-12p40
Patient no. SF Serum SF Serum
1 124 <8 314 82
2 388 8,040 1,238 19,305
3 <8 88 <31 <31
4 316 56 552 250
5 <8 <8 <31 180
6 3,770 240 2,790 818
7 154 146 646 886
8 <8 <8 <31 <31
9 354 400 772 1,266
10 <8 <8 <31 <31
11 56 <8 638 142
12 110 190 694 976
13 258 450 958 1,708
14 <8 <8 <31 <31
15 <8 <8 <31 <31
16 <8 <8 <31 <31
17 132 844 334 2,026
18 <8 150 <31 574
19 76 40 228 <31
20 335 1,030 1,976 3,274
21 <8 <8 86 <31
22 <8 <8 <31 <31
23 <8 <8 <31 <31
24 <8 <8 88 <31
25 <8 <8 <31 <31
26 <8 1,260 <31 2,400
27 <8 870 <31 1,740
28 <8 <8 <31 <31
29 318 3,580 744 8,260
30 3,400 15,300 7,860 80,100
31 <8 <8 <31 <31
32 90 156 526 946
33 2,985 1,240 4,380 1,896
34 <8 119 <31 846
35 <8 2,000 <31 29,160
Mean 372 1,038 724 4,502 
± SEM ± 160 ± 489 ± 259 ± 2,431
aCytokine concentrations were determined using cytokine specific
ELISAs. Each value is a mean of duplicate determinations. Limit values
were used for levels under detection limits.
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Figure 1
Production of IL-12p40 and IL-12p70 by synovial fluid (SF) macrophages and peripheral blood (PB) monocytes. Production of IL-12p70 (a,c) and
IL-12p40 (b,d) by SF macrophages from patients with rheumatoid arthritis and by normal PB monocytes, cultured for 72 hours in the presence of
CD154 transfectants (at a ratio of 1: 5 transfectants : responder cells), control J558L-cells (1: 5), LPS (1 µg/ml), or in medium only. Supernatants
were collected at the end of the culture period and the production of the cytokines was determined using ELISA. Individual values from each
experiment (n = 5–7) are shown. Each patient or control subject is represented by the same symbol in two panels. The detection limits for the














































































Effects of CD40 ligation and LPS on IL-10 and tumor necrosis factor alpha (TNF-α) production by synovial fluid (SF) macrophages
and normal peripheral blood (PB) monocytesa
SF macrophages PB monocytes
Incubation
Cytokine period (h) Medium J558L CD154 LPS Medium J558L CD154 LPS
IL-10 24 305 ± 193 161 ± 101 566 ± 208* 1,973 ± 788* 90 ± 49 99 ± 51 705 ± 465* 2,803 ± 938*
72 15 ± 11b 33 ± 19c 174 ± 55b,* 734 ± 357b 10 ± 4 18 ± 7 734 ± 414* 1,389 ± 752*
TNF-α 24 46 ± 39 20 ± 13 270 ± 62* 1,397 ± 437* 58 ± 35 44 ± 29 111 ± 40 3,410 ± 1,541*
72 <1 <1c 627 ± 220*,† 623 ± 344* 23 ± 14 19 ± 18 47 ± 19 242 ± 133*
aSF macrophages and PB monocytes were cultured with irradiated control J558L-cells (1: 5), CD154 tranfectants (1:5), or LPS (1 µg/ml) for 24 or
72 hours. Cytokine concentrations were determined using cytokine specific ELISAs. Results are presented as mean ± SEM pg/ml. n = 6 except
bn = 5 and cn = 4. *P < 0.05 when compared with cells cultured with transfectant controls or in medium only at the respective time point.
†P < 0.05 when compared with PB monocytes cultured in the presence of TNF-α for 72 hours. LPS, lipopolysaccharide.
IL-4 and IL-13 prime the production of IL-12p70 by
synovial fluid macrophages
IL-4 and IL-13 have been shown to enhance IL-12p70
production by DCs and monocytes/macrophages [1,6,7].
We have earlier shown that IL-4 increases the ability of SF
macrophages to function as antigen-presenting cells [28].
Therefore, we studied whether IL-4 and IL-13 would
induce IL-12p70 production. SF macrophages were
precultured in the presence of IL-4 or IL-13 for 72 hours
before stimulation with CD154 transfectants for 24 hours.
IL-4 significantly primed the production of IL-12p40 and
p70 (Fig. 3). Priming with IL-13 induced the production of
IL-12p40 significantly. In addition, IL-13 primed the pro-
duction of IL-12p70 in four of six samples studied. In two
samples, the induction was clear, from < 8 pg/ml to 255
and 384 pg/ml, and in two samples from < 8 pg/ml to 23
and 28 pg/ml.
IFN-γ primes IL-12p70 production by peripheral blood
monocytes but not by synovial fluid macrophages
IFN-γ is known to effectively prime macrophages to
produce IL-12p70 [1]. We therefore studied whether pre-
treatment with IFN-γ before CD40 ligation would induce
IL-12p70 production by SF macrophages. Cells were
precultured in the presence of 100 ng/ml IFN-γ for
16 hours before stimulation with CD154 transfectants for
24 hours. In only one of the samples studied did SF
macrophages produce IL-12p70, and this was at a low
concentration (Fig. 4). In contrast, CD40 ligation induced
IL-12p70 production in all the samples of PB monocytes
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Table 3
Effect of CD40 ligation on cytokine production by dendritic cells (DCs) derived from synovial fluid (SF) macrophages or normal
peripheral blood (PB) monocytesa
SF-derived DCsb PB-derived DCsc
Cytokine J558L CD154 J558L CD154
IL-12p70 <8 1,072 ± 632 <8 271 ± 52
IL-12p40 61 ± 30 24,670 ± 8,127 47 ± 12b 18,432 ± 2,344b
TNF-α <1 1,570 ± 906 4 ± 2 1,598 ± 373
IL-10 4 ± 3 223 ± 43 8 ± 3 430 ± 144
aPB monocytes and SF macrophages were cultured with IL-4 and granulocyte/macrophage-colony-stimulating factor for 7 days, and irradiated
control J558L-cells (1: 5) or CD154 tranfectants (1: 5) were added for 24 hours. Cytokine concentrations were determined using cytokine specific
ELISAs. Results are presented as mean ± SEM pg/ml. bn = 3; cn = 4 except as otherwise indicated.
Figure 2
RT-PCR analysis of IL-12p35 and IL-12p40 mRNA expression in synovial fluid (SF) macrophages. Total RNA from SF macrophages (SF M∅),
either freshly isolated or incubated with CD154 transfectants or control J558L-cells for 6 or 24 hours. RNA was subjected to reverse transcription,
and complementary DNA was amplified by primers specific for IL-12p35, IL-12p40, and constitutively expressed β-actin. cDNA specific for IL-
12p35 and IL-12p40 was analyzed using Southern blotting. Reverse transcriptase was omitted from the control reactions. Analysis of SF
macrophages from two patients is presented. As a positive control, expression of IL-12p35 and p40 mRNA was analyzed in CD154-stimulated
DCs derived from SF macrophages. J558L cells, CD154 transfectants, and aqua were studied as negative controls. RT+ and RT–, incubation with
and without reverse transcriptase, respectively.
after pretreatment with IFN-γ. Results were similar when
LPS was used as a stimulus (data not shown). Lower
levels of IL-12p70 were produced by PB monocytes when
a lower concentration of IFN-γ (10 ng/ml) was used for
priming (data not shown). These results show that IFN-γ is
not capable of priming SF macrophages to produce
IL-12p70.
Anti-TNF-α treatment increases IL-12p70 production in
synovial fluid macrophages
Several cytokines have been shown to inhibit the produc-
tion of IL-12p70. IL-10 and TNF-α are among them
[1,12,13], and because these cytokines are present at
high levels in RA joints, we studied whether blocking of
their effect would induce IL-12p70 secretion in SF
macrophages. Addition of neutralizing mAbs to IL-10 or
TNF-α in the culture 24 hours before, or simultaneously
with, CD154 transfectants did not affect the production of
IL-12p70 (data not shown). However, SF macrophages
precultured with neutralizing anti-TNF-α mAbs for
24 hours and then primed with IFN-γ for 16 hours before
stimulation with CD154 transfectants produced, in two of
three experiments, significantly higher levels (420, 1146,
and < 8 pg/ml) of IL-12p70 than those cells precultured in
the presence of the control Abs (< 8, 40, and < 8 pg/ml,
respectively). Preculturing the cells with neutralizing anti-
IL-10 mAbs before IFN-γ priming had no effect on
IL-12p70 production (data not shown).
Discussion
As we have previously shown, SF macrophages express
increased levels of CD40 [28]. Synovial T cells express
CD154 [32,33], indicating that synovial T cells can acti-
vate antigen-presenting cells via CD40. In the present
study, we show that SF macrophages produce IL-12p40
but not the IL-12p70 heterodimer after CD40 ligation. Our
data support the idea that the production of IL-12p40 and
p70 are independently regulated and indicate that despite
the augmented CD40 expression, triggering of CD40
does not induce IL-12p70 production in SF macrophages.
We also provide evidence that CD40 ligation upregulates
the transcription of p40 more consistently and to a higher
level than p35 transcription, suggesting that the lack of
p35 transcription limits p70 protein production. We also
show that DCs derived from SF macrophages produce
high levels of IL-12p70. These data suggest that SF
macrophages contain the progenitors of myeloid DCs that
are the main producers of IL-12p70 in the synovium. This
is in line with recent findings showing that SF contains
DCs and their myeloid progenitors that can differentiate
into functional DCs [34]. The role of IL-12p40 produced
by SF macrophages remains unclear. IL-12p40 homod-
imer could inhibit the function of IL-12p70 in the synovium
[1]. Also, a possibility remains that the excess of IL-12p40
reflects the production of IL-23 composed of its own p19
subunit and p40 [35].
IL-4 and IL-13 share many functions. While IL-4 produc-
tion in inflamed joints has not been consistently shown, IL-
13 produced by SF macrophages has been detected at
significant levels [36]. We observed that SF macrophages
preincubated with IL-4 or IL-13 produced IL-12p70 after
CD40 ligation. Also, IL-12p40 production was increased,
suggesting that IL-4 and IL-13 enhance the production of
both p35 and p40 subunits. In line with our results, IL-4
and IL-13 have been shown to enhance the production of
IL-12 p70 in monocytes when the cells are primed for
more than 24 hours [1]. Likewise, IL-4 has been shown to
enhance CD154-induced IL-12p70 production in human
thymic and monocyte-derived DCs and in monocyte-
derived macrophages [6,7]. We have previously shown
that SF macrophages cultured in the presence of IL-4
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Figure 3
Production of IL-12p40 and p70 by synovial fluid (SF) macrophages
precultured with IL-4 and IL-13. SF macrophages were cultured in the
presence of IL-4 (n = 9) or IL-13 (n = 6) (100 U/ml) or in medium only
(n = 9) for 72 hours before addition of CD154 transfectants (at a ratio
of 1:5 transfectants : SF macrophages) or control J558L cells (1: 5) for
a further 24 hours. Supernatants were collected at the end of the
culture and the production of IL-12p70 (a) and p40 (b) was
determined using ELISA. Individual values from each experiment are
shown; each patient is represented by the same symbol in the two
panels. Cells stimulated with control J558L did not produce IL-12p40














































downregulate the expression of CD14, upregulate the
expression of CD40, CD80, CD86, and HLA-DR, and
acquire increased capacity to stimulate allogeneic T cells
[28]. The observed induction of IL-12p70 production by
IL-4 is likely to be associated with the differentiation of SF
macrophages into DCs. Like IL-4, IL-13 together with GM-
CSF induces monocytes to differentiate into DCs [37].
Although IL-4 induces Th2 differentiation in naive T cells,
the capacity of IL-4 to direct either SF or PB T cells from
RA patients towards a Th2 phenotype is impaired [17,38].
Present results suggest that, in some circumstances, both
IL-4 and IL-13 may in fact promote Th1 responses in the
synovium by inducing synovial macrophages to differenti-
ate into IL-12p70-producing DCs.
In contrast to IL-4 and IL-13, priming with IFN-γ was not
observed to activate SF macrophages to produce
IL-12p70, although IFN-γ is known to prime normal
macrophages to produce IL-12p70 [1]. As expected, we
observed high IL-12p70 production in IFN-γ-primed
normal PB monocytes. This suggests that SF
macrophages are unresponsive to IFN-γ and/or CD154,
two signals provided by activated T cells and needed to
produce high levels of IL-12p70. This finding is consistent
with our observation that IL-12 concentrations are lower in
SF than serum. This may suggest a novel counter-regula-
tory mechanism in RA and perhaps in other situations with
chronic inflammation. Since the frequency of IFN-γ-pro-
ducing Th1/Th0 cells is higher in RA joints than in PB
[15–17], our data suggest that other Th1-promoting
cytokines, such as IL-15 and IL-18, which have been
detected at high levels in RA synovium [19], play an
important role in RA. Substantial evidence indicates that
TNF-α is a major proinflammatory cytokine in RA [39].
However, we found that neutralization of TNF-α before
priming with IFN-γ activated the production of IL-12p70.
In line with our results, TNF-α has been previously shown
to inhibit LPS- or Staphylococcus aureus-induced IL-
12p70 production by IFN-γ primed human monocyte-
derived macrophages [13]. Our finding implies that
TNF-α does not have a purely proinflammatory function in
RA and emphasizes that TNF-α may be involved in sup-
pression of IL-12 production in chronic inflammation [40].
In the interpretation of these findings, the potential effect
of treatment of the RA patients on IL-12 production
should be taken into account. It would be interesting to
know how the production of IL-12 is regulated during the
early phase of RA.
Conclusion
We have shown that SF macrophages do not produce IL-
12p70 after CD40 ligation. However, IL-4 and IL-13, but
not IFN-γ, are able to prime p70 production in these cells.
Lack of p70 production may be due to the insufficient
induction of p35 transcription. It seems that DCs in the
synovium are the main producers of IL-12p70. These
results reveal novel regulatory mechanisms in the complex
cytokine network in RA synovium.
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Figure 4
Production of IL-12p70 after priming with IFN-γ. Synovial fluid (SF) macrophages (n = 6) and normal peripheral blood (PB) monocytes (n = 7) were
precultured in the presence of IFN-γ (100 ng/ml) for 16 hours and then CD154 transfectants (at a ratio of 1: 5 transfectants : macrophages) or
control J558L-cells (1: 5) were added for the last 24 hours of culture. Supernatants were collected at the end of the culture and the production of
IL-12p70 was determined using ELISA. Individual values from each experiment are shown.
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